The text starts here.

News Release

May 14, 2002

Eisai Establishes Clinical Research Subsidiary in the United States

Tokyo (May 14, 2002) Eisai Co., Ltd. (President & CEO: Haruo Naito) announced that a new clinical research company will be established in the United States to further accelerate clinical development. Previously, clinical development functions in the U.S. were part of Eisai Inc.(President: William Sheldon) The new company will be called Eisai Medical Research Inc.

Eisai focuses on meeting global unmet medical needs and to rapidly discover and develop pharmaceutical products. In order to strengthen Eisai's clinical research organizational structure, this new operation will be established.

< U.S. Clinical Research Subsidiary Outline >
1. Name : Eisai Medical Research Inc.
2. Capital : $1 million
3. Presiden : Mindell Seidlin (Currently Vice President, R&D, Eisai Inc.)
4. Location : Teaneck, New Jersey
5. Est. Date : June 3, 2002 (planned)
6. Structure : Non-public

Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. The Company reported sales of over $3.2 billion in 2001 with approximately 13 percent of sales spent for research and development.